Humanized anti-IL-1R3 antibody and methods of use
An antibody that specifically binds to IL-1R3, comprising an antibody heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. A pharmaceutical composition is provided comprising the said antibody and a pharmaceutically acceptable diluent, carrier or excipient. Also said antibody for use in treating a disease or disorder in a subject in need thereof. The disease or disorder may be an autoimmune or autoinflammatory disease or disorder.
1. An antibody that specifically binds to IL-1R3, comprising an antibody heavy chain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 2.
2. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.
3. An isolated nucleic acid molecule encoding an antibody that specifically binds to IL-1R3,
wherein the antibody comprises a heavy chain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 2.
4. An expression vector comprising the nucleic acid molecule of claim 3 .
5. A host cell comprising the expression vector of claim 4 .
6. The host cell of claim 5 , which is a Chinese hamster ovary (CHO) cell.
7. A method of manufacturing an antibody that specifically binds to IL-1R3, comprising the steps of:
(i) transfecting a host cell using an isolated nucleic acid molecule encoding said antibody or an expression vector comprising a nucleic acid molecule encoding said antibody;
(ii) cultivating the host cell under conditions allowing expression of the antibody;
(iii) recovering the antibody; and
(iv) optionally further purifying and/or modifying and/or formulating the antibody;
wherein the antibody comprises a heavy chain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 2.
8. The method of claim 7 , wherein the host cell is a Chinese hamster ovary (CHO) cell.
9. The method of claim 7 , wherein the method comprises: (v) further formulating the antibody,
wherein the formulating comprises combining the antibody with a pharmaceutically acceptable diluent, carrier or excipient.
10. The method of claim 7 , wherein an expression level of the antibody is greater than an expression level of an anti-IL-1R3 antibody comprising a human IgG1 Fc region,
wherein the human IgG1 Fc region comprises amino acid substitutions L234A and L235A, according to EU numbering.
11. An antibody produced by the method of claim 7 .
12. A method of treating a disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of an antibody that specifically binds to IL-1R3,
wherein the antibody comprises a heavy chain comprising SEQ ID NO: 1 and a light chain comprising SEQ ID NO: 2,
wherein the disease or disorder is an autoimmune, autoinflammatory, neoplastic, inflammatory, and/or fibrotic disease or disorder.
13. The method of claim 12 wherein the disease or disorder is a neoplastic disease or disorder.
14. The method of claim 12 , wherein the disease or disorder is an inflammatory skin disease.
15. The method of claim 8 , wherein the host cell is a CHO DXB11 cell.
16. The method of claim 8 , wherein the method comprises:
(v) further formulating the antibody,
wherein the formulating comprises combining the antibody with a pharmaceutically acceptable diluent, carrier or excipient.
17. The method of claim 15 , wherein the method comprises:
(v) further formulating the antibody,
wherein the formulating comprises combining the antibody with a pharmaceutically acceptable diluent, carrier or excipient.
18. The method of claim 8 , wherein an expression level of the antibody is greater than an expression level of an anti-IL-1R3 antibody comprising a human IgG1 Fc region,
wherein the human IgG1 Fc region comprises amino acid substitutions L234A and L235A, according to EU numbering.
19. The method of claim 15 , wherein an expression level of the antibody is greater than an expression level of an anti-IL-1R3 antibody comprising a human IgG1 Fc region,
wherein the human IgG1 Fc region comprises amino acid substitutions L234A and L235A, according to EU numbering.
20. An antibody produced by the method of claim 8 .
21. An antibody produced by the method of claim 15 .
22. The host cell of claim 5 , wherein the host cell is a CHO DXB11 cell.